Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Impulsin
2. Mimyx
3. N-(2-hydroxyethyl)palmitate
4. N-palmitoylethanolamine
5. Palmidrol
6. Palmitylethanolamide
1. Palmidrol
2. 544-31-0
3. N-(2-hydroxyethyl)hexadecanamide
4. Palmitoyl Ethanolamide
5. Impulsin
6. Palmitamide Mea
7. N-palmitoylethanolamine
8. Loramine P 256
9. Hydroxyethylpalmitamide
10. Palmitic Acid Monoethanolamide
11. N-(2-hydroxyethyl)palmitamide
12. Palmitoyl-ea
13. Palmitylethanolamide
14. Palmidrolum
15. Hexadecanamide, N-(2-hydroxyethyl)-
16. Palmidrol [inn]
17. Monoethanolamine Palmitic Acid Amide
18. Levagen
19. Anandamide (16:0)
20. N-palmitoyl Ethanolamine
21. Palmitic Monoethanolamide
22. Palmdrol Prodes
23. N-hexadecanoylethanolamine
24. Palmitinsaeure-beta-hydroxyethylamid
25. Nsc 23320
26. Hexadecanoyl Ethanolamide
27. Nsc-23320
28. N-hexadecanoyl-ethanolamine
29. N(2-hydroxyethyl)palmitide
30. Am 3112
31. 6r8t1udm3v
32. N(2-hydroxyethyl) Palmitide
33. N-(2-hydroxyethyl)-palmitide
34. Chebi:71464
35. Fsd-201
36. Palmidrol (inn)
37. Ncgc00015793-03
38. Am 3112;loramine P 256;mackpeart Dr 14v
39. Dsstox_cid_22254
40. Dsstox_rid_79975
41. Dsstox_gsid_42254
42. Mimyx
43. Palmidrolum [inn-latin]
44. Cas-544-31-0
45. Sr-01000076055
46. Einecs 208-867-9
47. Unii-6r8t1udm3v
48. N-(2-hydroxyethyl) Hexadecanamide
49. Hexadecanamide,n-(2-hydroxyethyl)-
50. Mackpeart Dr 14v
51. Mfcd00020562
52. Anandamide C16:0
53. 2-palmitoylaminoethanol
54. Palmdrol Prodes (tn)
55. Tocris-0879
56. N-palmitoyl Ethanolamide
57. N-hexadecyl-ethanolamine
58. Palmidrol [mi]
59. Lopac-p-0359
60. Palmidrol [mart.]
61. Palmitoylethanolamide-[d4]
62. Palmityoletanolamide (pea)
63. 2-palmitamidoethanol
64. Palmidrol [who-dd]
65. Cbiol_002043
66. Lopac0_000905
67. Bspbio_001454
68. Kbiogr_000174
69. Kbioss_000174
70. Mls002153421
71. Schembl120518
72. Palmitamide Mea [inci]
73. Bml2-b10
74. Chembl417675
75. Gtpl3622
76. Am-3112
77. Dtxsid4042254
78. Palmidrol
79. N-palmitoylethanolamine
80. Schembl19511663
81. Bdbm29083
82. Kbio2_000174
83. Kbio2_002742
84. Kbio2_005310
85. Kbio3_000347
86. Kbio3_000348
87. Bio1_000329
88. Bio1_000818
89. Bio1_001307
90. Bio2_000174
91. Bio2_000654
92. Hms1361i16
93. Hms1791i16
94. Hms1989i16
95. Hms2234l19
96. Hms3264c10
97. Hms3266n08
98. Hms3374k03
99. Hms3402i16
100. Hms3411b14
101. Hms3649l03
102. Hms3675b14
103. Pharmakon1600-01506156
104. Bcp29005
105. Cs-d1253
106. Nsc23320
107. Zinc8035017
108. Tox21_110222
109. Ana(16:0)
110. Lmfa08040013
111. Nae(16:0)
112. Nsc760371
113. S4708
114. Stl454872
115. Akos002676363
116. Tox21_110222_1
117. Ccg-204987
118. Db14043
119. Lp00905
120. Nsc-760371
121. Sdccgsbi-0050880.p002
122. Idi1_033924
123. S10398
124. Ncgc00015793-01
125. Ncgc00015793-02
126. Ncgc00015793-04
127. Ncgc00015793-05
128. Ncgc00015793-06
129. Ncgc00015793-07
130. Ncgc00015793-08
131. Ncgc00015793-09
132. Ncgc00015793-10
133. Ncgc00015793-12
134. Ncgc00024840-01
135. Ncgc00024840-02
136. Ncgc00024840-05
137. Ncgc00024840-06
138. Ncgc00024840-07
139. Ncgc00024840-08
140. Ncgc00024840-09
141. As-14094
142. Hy-20685
143. Palmitoylethanolamide [nflis-drug]
144. Smr000058371
145. Hexadecanoic Acid (2-hydroxy-ethyl)-amide
146. B6485
147. Eu-0100905
148. Ft-0778178
149. P2670
150. D08328
151. P 0359
152. Ab00918319_06
153. A904411
154. Q2159860
155. Sr-01000076055-1
156. Sr-01000076055-3
157. Sr-01000076055-7
158. Brd-k68095457-001-04-4
159. Z2687203832
Molecular Weight | 299.5 g/mol |
---|---|
Molecular Formula | C18H37NO2 |
XLogP3 | 6.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 16 |
Exact Mass | 299.282429423 g/mol |
Monoisotopic Mass | 299.282429423 g/mol |
Topological Polar Surface Area | 49.3 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 219 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Cannabinoid Receptor Agonists
Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS. (See all compounds classified as Cannabinoid Receptor Agonists.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: SCI-110
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2024
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SciSparc Secures FDA Green Light for Phase IIb Clinical Trial in Tourette Syndrome
Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Brand Name : SCI-110
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2024
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: SCI-110
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2024